Technical Analysis for NKTR - Nektar Therapeutics

Grade Last Price % Change Price Change
grade C 36.51 -3.92% -1.49
NKTR closed down 3.92 percent on Friday, December 14, 2018, on 69 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NKTR trend table...

Date Alert Name Type % Chg
Dec 14 Bollinger Band Squeeze Range Contraction 0.00%
Dec 13 20 DMA Resistance Bearish -3.92%
Dec 13 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.92%
Dec 13 Bollinger Band Squeeze Range Contraction -3.92%
Dec 13 NR7 Range Contraction -3.92%
Dec 13 Inside Day Range Contraction -3.92%
Dec 12 20 DMA Resistance Bearish -1.24%
Dec 12 Shooting Star Candlestick Bearish -1.24%
Dec 12 Pocket Pivot Bullish Swing Setup -1.24%
Dec 12 Bollinger Band Squeeze Range Contraction -1.24%

Older signals for NKTR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist that is in Phase 3 clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase 2 clinical trail to treat gram-negative pneumonias; NKTR-181, a mu-opioid analgesic molecule, which is in Phase 2 clinical trail for chronic pain; and NKTR-192 that is in Phase 1 to treat acute pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase 3 clinical trial for the treatment of metastatic breast cancer; in Phase 2 clinical trail for ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 for the treatment of chronic pain; NKTR-171 to treat neuropathic pain; and NKTR-214, a cytokine immunostimulatory therapy for the treatment of oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. Further, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, MAP Pharmaceuticals, Merck, Pfizer, Roche, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.
Is NKTR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 111.36
52 Week Low 33.5
Average Volume 2,484,935
200-Day Moving Average 63.9769
50-Day Moving Average 40.7818
20-Day Moving Average 38.0135
10-Day Moving Average 37.852
Average True Range 2.1039
ADX 24.74
+DI 15.2854
-DI 22.592
Chandelier Exit (Long, 3 ATRs ) 34.9983
Chandelier Exit (Short, 3 ATRs ) 41.8817
Upper Bollinger Band 40.24
Lower Bollinger Band 35.787
Percent B (%b) 0.16
BandWidth 11.714259
MACD Line -1.0414
MACD Signal Line -1.1909
MACD Histogram 0.1495
Fundamentals Value
Market Cap 5.71 Billion
Num Shares 156 Million
EPS -1.40
Price-to-Earnings (P/E) Ratio -26.08
Price-to-Sales 27.79
Price-to-Book 1075.45
PEG Ratio 3.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.73
Resistance 3 (R3) 38.95 38.42 38.36
Resistance 2 (R2) 38.42 37.86 38.32 38.24
Resistance 1 (R1) 37.47 37.51 37.21 37.25 38.11
Pivot Point 36.94 36.94 36.81 36.84 36.94
Support 1 (S1) 35.99 36.38 35.73 35.77 34.91
Support 2 (S2) 35.46 36.03 35.36 34.78
Support 3 (S3) 34.51 35.46 34.66
Support 4 (S4) 34.29